Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal while Goodwin Procter represented Redmile Group. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised ACELYRIN on the deal. ACELYRIN announced the completion of its $300 million Series C financing round which was led by Access Biotechnology with participation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio on the deal. BridgeBio announced its definitive agreement with an undisclosed purchaser to sell its rare pediatric disease Priority Review Voucher for $110...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised The Routing Company on the deal. The Routing Company announced its $15 million Series A financing led by Galvanize Climate Solutions. The Routing Company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Global Blood Therapeutics on the deal. Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Qilu Pharmaceutical on the deal. Qilu Pharmaceutical, one of the leading pharmaceutical companies in China (“Qilu”), announced its exclusive licensing agreement and strategic partnership...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
You must be a Standard 1 Year member to access this content.
